Cost‐Effectiveness of Automated Insulin Delivery Systems in Paediatrics, T1D and T2D Adults Across Four Nordic Countries
Diabetes, Obesity and Metabolism · 2026
DOI: 10.1111/dom.70658 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diabetes, Obesity and Metabolism, 2026. Verfasst von Johan Jendle und 5 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine, Örebro University, Örebro, Sweden. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Insulin, Insulin Infusion Systems. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Aims
This study evaluated long‐term cost‐effectiveness of automated insulin delivery (AID) systems versus multiple daily injections (MDI) + CGM in children with type 1 diabetes (T1D), adults with T1D and insulin‐treated individuals with type 2 diabetes (T2D) across Denmark, Finland, Norway and Sweden. Materials and Methods Clinical outcomes and economic footprints were analysed for horizons up to 50 years from a healthcare system perspective using the IQVIA Core Diabetes Model. Five patient profiles were modelled: T1D paediatrics (T1D‐Paed), T1D adults with high baseline HbA1c (T1D‐Adult), real‐world evidence in T1D adults with lower baseline HbA1c (T1D‐Adult RWE ), T2D adults (T2D‐Adult) and older T2D adults (T2D‐Elder). Costs were inflated to July 2024, with 3% annual discounting. Sensitivity analyses explored scenarios varying time horizons and HbA1c effect sizes and inclusion of hypoglycaemia rates.
Results
AID systems were estimated to lead to a reduction in diabetes‐related complications in all groups, most notably in the T1D‐Adult group (318 vs. 542 complications per 100 individuals). Improvements translated into lifetime cost savings (€1435 to €26 259), increased life expectancy (LE) and more quality‐adjusted life years (QALYs). Incremental cost‐effectiveness ratios (ICERs) remained below willingness‐to‐pay thresholds in all countries (from €14 695/QALY for T1D‐Adult in Finland to €56 711/QALY for T1D‐Adult RWE in Denmark), confirming AID is cost‐effective across all groups in the Nordic region.
Conclusions
AID therapy consistently projected reduced diabetes‐related complications while remaining cost‐effective across a broad spectrum of diabetes patient profiles in the Nordic region. These findings strengthen the case towards widespread integration of AID technology into national diabetes care frameworks.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Medicine, Örebro University, Örebro, Sweden.
- Steno Diabetes Center Copenhagen, Herlev, Denmark.
- University of Copenhagen, Copenhagen, Denmark.
- Finish Diabetes Association, Tampere, Finland.
- Department of Research and Innovation, Fonna Hospital Trust Haugesund, Haugesund, Norway.
- Mohn Center for Diabetes Precision Medicine, Department of Clinical Science, University of Bergen, Bergen, Norway.
ORCID-Profile: Maria-Eleni Syleouni
Zitieren
APA
Jendle, J., Nørgaard, K., Pimiä, E., Bratke, H., Mirón, A. K., & Syleouni, M. E. (2026). Cost‐Effectiveness of Automated Insulin Delivery Systems in Paediatrics, T1D and T2D Adults Across Four Nordic Countries. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.70658
Vancouver
Jendle J, Nørgaard K, Pimiä E, Bratke H, Mirón AK, Syleouni ME. Cost‐Effectiveness of Automated Insulin Delivery Systems in Paediatrics, T1D and T2D Adults Across Four Nordic Countries. Diabetes, Obesity and Metabolism. 2026. doi:10.1111/dom.70658
BibTeX
@article{Jendle2026,
author = {Jendle, Johan and Nørgaard, Kirsten and Pimiä, Elina and Bratke, Heiko and Mirón, Aesha Khan and Syleouni, Maria-Eleni},
title = {Cost‐Effectiveness of Automated Insulin Delivery Systems in Paediatrics, T1D and T2D Adults Across Four Nordic Countries},
journal = {Diabetes, Obesity and Metabolism},
year = {2026},
doi = {10.1111/dom.70658}
}
EUVIMED